The PReDicT Project


Following a successful UK clinical study, P1vital secured €4m from the EU Horizon 2020 SME program in recognition of the positive impact in managing the treatment of depression and potential of highly significant cost savings.

The PReDicT Test Reduction Cycle

Click to enlarge – The PReDicT Test Reduction Cycle

The award, under grant agreement No 696802, will fund the PReDicT Project  to conduct clinical validation, health economic research and commercial development at the European level to support market launch of its lead product, the Predicting Response to Depression Treatment or the P1vital® PReDicT Test, a breakthrough medical software device.

To learn more about the PReDicT Project, visit our dedicated PReDicT Project website.

H2020 Emblem